Dallas_hospital_confirms_first_EbolaThe World Health Organization said Wednesday that the manufacture, financing and distribution of a large-scale Ebola vaccine is not possible until the middle of next year at the earliest.  WHO is expediting Phase 1 and Phase 2 trials on two highly promising experimental Ebola vaccines, hoping to obtain approval next February. On Tuesday, the Centers for Disease Control reported the first case of the current strain of Ebola brought to the U.S. by a traveler. “The Ebola outbreak currently ravaging parts of West Africa is the most severe acute public health emergency in modern times,” WHO said in a statement issued from Geneva. “Never before in recent history has a biosafety level 4 pathogen infected so many people so quickly, over such a wide geographical area, for so long.” One of the vaccines, cAd3-ZEBOV, has been developed by GlaxoSmithKline in collaboration with the U.S. National Institute of Allergy and Infectious Diseases. It uses a chimpanzee-derived adenovirus vector with an Ebola virus gene inserted. More